Abaxis (NASDAQ:ABAX) will report earnings after markets close on Thursday, July 25th. Abaxis, Inc. develops, manufactures, and markets portable blood analysis systems for use in any patient care setting. The Company’s systems provide clinicians with rapid blood constituent measurements. Abaxis currently markets the VetScan for veterinary use and the Piccolo for human medical use. The Company’s products are sold in the United States, as well as in Europe and Japan.
Here is your Cheat Sheet to Abaxis Earnings:
Earnings Expectations: Analysts expect earnings of $0.23 per share on revenues of $49.13 million. Currently, the company’s P/E ratio stands at 40.65.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.26 to a profit $0.24. For the current year, the average estimate is a profit of $1.06, which is worse than the estimate ninety days ago.
Here’s how Abaxis has been performing on an annual basis:
|Revenue ($) in millions||106||125||144||157||186|
|Diluted EPS ($)||0.54||0.58||0.64||0.58||1.23|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||42.01||44.26||49.80||49.95|
|Diluted EPS ($)||0.13||0.58||0.22||0.30|
Abaxis has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)